Elamipretide (SS-31, Bendavia, MTP-131) is a synthetic, cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) engineered to accumulate in the inner mitochondrial membrane. It is the most clinically advanced member of a small class of mitochondria-targeted research peptides, and in September 2025 it became the first cardiolipin-directed therapeutic to receive any regulatory approval: the US Food and Drug Administration granted accelerated approval to Forzinity (elamipretide hydrochloride) to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. [r3]

That is a US regulatory event, granted on a surrogate endpoint in an ultra-rare disease and contingent on a confirmatory trial. In the UK, elamipretide has no marketing authorisation and is not an MHRA-approved medicine. This explainer sets out what the mechanism claims, what the controlled human trials actually found, why Peptide Data grades the compound Moderate rather than Strong, and where it sits under UK law. [r6]

01 — Mechanism: a cardiolipin-directed tetrapeptide

Elamipretide binds reversibly to cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, where it is required for the assembly and stability of the electron-transport-chain complexes and supercomplexes. By stabilising cardiolipin, the peptide is proposed to preserve cristae structure, improve electron-transport efficiency, reduce electron leak and reactive oxygen species production, and inhibit cytochrome c release — the step that commits a cell to mitochondria-mediated apoptosis. [r6]

The mechanism is unusually well specified for a research peptide, and it has generated a broad preclinical literature, including canine and rodent heart-failure models. [r7] But a plausible mechanism is not evidence of clinical benefit; the question is what the controlled human trials showed.

02 — The human evidence: one positive ultra-rare signal, one failed Phase 3

MMPOWER-3 — primary mitochondrial myopathy (Phase 3). The largest randomised test of elamipretide enrolled 218 adults with genetically confirmed primary mitochondrial myopathy and randomised them to a fixed 40 mg daily subcutaneous dose of elamipretide or placebo for 24 weeks. The trial did not meet either primary endpoint: the between-group difference in the 6-minute walk test at week 24 was −3.2 metres (95% CI −18.7 to 12.3; p = 0.69), and there was no statistically significant change in the total fatigue score on the PMMSA. A pre-specified post hoc analysis suggested better 6-minute-walk performance in the subgroup whose myopathy was caused by nuclear-DNA (nDNA) variants, but not in those with mitochondrial-DNA changes — a hypothesis-generating finding, not a demonstrated effect. [r1]

TAZPOWER — Barth syndrome (Phase 2/3 with open-label extension). Barth syndrome is an X-linked disorder of cardiolipin metabolism caused by tafazzin-gene mutations — mechanistically the most natural fit for a cardiolipin-binding peptide. In a 12-patient crossover trial, elamipretide did not significantly improve the 6-minute walk distance or the Barth-syndrome symptom-assessment fatigue score during the randomised period. During the open-label extension, knee-extensor muscle strength improved from baseline; among the 10 patients who entered the extension, median change in muscle strength at week 168 was 63 newtons (range 38–78). It was this open-label signal, rather than a controlled endpoint, that supported the US accelerated approval. [r2][r4][r5]

03 — Why the grade is Moderate, not Strong

Peptide Data's four-tier system reserves Strong for compounds with consistent, well-powered, controlled human evidence of clinical benefit. Elamipretide does not meet that bar:

  • Its largest controlled trial (MMPOWER-3) was negative on both primary endpoints.
  • The indication for which it is approved in the US rests on an open-label, uncontrolled muscle-strength signal in a 12-patient trial.
  • The approval is accelerated and conditional — continued marketing depends on confirmatory data, which is being collected in a post-approval trial. [r3][r4]
  • There are no controlled human data in healthy populations.

What elamipretide does have is a coherent mechanism, a consistent safety profile across trials (injection-site reactions being the most common adverse event, with hypersensitivity reactions also reported), and one genuine clinical signal in a disease defined by the very pathway the peptide targets. That combination — real but narrow and partly uncontrolled human data — is what Moderate denotes. [r4][r6]

04 — Regulatory position: a US accelerated approval, no UK licence

Elamipretide is not licensed in the UK. There is no MHRA marketing authorisation for elamipretide or Forzinity, it is not available on NHS prescription, and it is not a controlled drug under the Misuse of Drugs Act 1971. Under the Human Medicines Regulations 2012, supplying an unlicensed medicine for human use in the UK is an offence unless it falls within a specific exemption (for example, a licensed clinical trial or a named-patient arrangement). Research-grade elamipretide sold by chemical suppliers is intended for laboratory research only; purchasing it for personal therapeutic use is not lawful in the UK, and such material carries no guarantee of identity, sterility or purity. [r6]

The US approval does not travel. A medicine authorised by the FDA is not thereby authorised in Great Britain, and the accelerated-approval basis — a surrogate endpoint in an ultra-rare paediatric disease — is not a template that transfers to general or lifestyle use.

05 — What the evidence does not support

Elamipretide is frequently discussed in longevity and mitochondrial-"energetics" circles as a general performance or anti-ageing compound. The published human evidence does not support that framing. The controlled trials were conducted in people with genetically defined mitochondrial disease; there are no controlled data on mitochondrial function, exercise capacity or ageing endpoints in healthy adults, and the Phase 3 programme in the broader primary-mitochondrial-myopathy population was negative. Preclinical findings in heart-failure and ageing models are hypothesis-generating only. [r1][r7]

Peptide Data does not provide dosing, administration or self-use guidance for any compound. Elamipretide is described here as a research subject, in a research-use-only context.

Research-use-only statement

Elamipretide is an investigational compound. It is not licensed for human consumption in the UK, and nothing on this page is medical advice or a recommendation to use it. All content is provided for research and educational purposes only.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.